Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -6.35% | -16.31% |
04-02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
04-02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 387M | |
+8.69% | 220B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 107B | |
+0.27% | 63.05B | |
+12.72% | 51.74B | |
+3.96% | 50.47B | |
+0.40% | 40.91B | |
+15.03% | 40.59B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte Licenses Cell-based Platform Technologies to Catamaran Bio